EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events

Bertram Pitt, Deepak L Bhatt, Michael Szarek, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Adriaan A Voors, Marco Metra, Lars H Lund, Michel Komajda und 11 weitere

JACC: Heart Failure · 2023-08 · 11 (8) · 879-889

DOI: 10.1016/j.jchf.2023.05.026 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JACC: Heart Failure, 2023-08. Verfasst von Bertram Pitt und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine (Emeritus), University of Michigan School of Medicine, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Heart Failure. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Approximately 25% of patients admitted to hospitals for worsening heart failure (WHF) are readmitted within 30 days. OBJECTIVES: The authors conducted a post hoc analysis of the SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post-WHF) trial to evaluate the efficacy of sotagliflozin versus placebo to decrease mortality and HF-related events among patients who began study treatment on or before discharge from their index hospitalization. METHODS: The main endpoint of interest was cardiovascular death or HF-related event (HF hospitalization or urgent care visit) occurring within 90 and 30 days after discharge for the index WHF hospitalization. Treatment comparisons were by proportional hazards models, generating HRs, 95% CIs, and P values. RESULTS: Of 1,222 randomized patients, 596 received study drug on or before their date of discharge. Sotagliflozin reduced the main endpoint at 90 days after discharge (HR: 0.54 [95% CI: 0.35-0.82]; P = 0.004) and at 30 days (HR: 0.49 [95% CI: 0.27-0.91]; P = 0.023) and all-cause mortality at 90 days (HR: 0.39 [95% CI: 0.17-0.88]; P = 0.024). In subgroup analyses, sotagliflozin reduced the 90-day main endpoint regardless of sex, age, estimated glomerular filtration rate, N-terminal pro-B-type natriuretic peptide, left ventricular ejection fraction, or mineralocorticoid receptor agonist use. Sotagliflozin was well-tolerated but with slightly higher rates of diarrhea and volume-related events than placebo. CONCLUSIONS: Starting sotagliflozin before discharge in patients with type 2 diabetes hospitalized for WHF significantly decreased cardiovascular deaths and HF events through 30 and 90 days after discharge, emphasizing the importance of beginning sodium glucose cotransporter treatment before discharge.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Heart FailureHumansHospitalizationStroke VolumeVentricular Function, LeftGlycosides

Stichwörter der Autor:innen

SGLT2 inhibitordual SGLT1 and SGLT2 inhibitorheart failure-related eventshospital readmissionmortalitysotagliflozin

Substanzen

(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triolGlycosides

Autor:innen und Institutionen

  • Department of Internal Medicine (Emeritus), University of Michigan School of Medicine, Ann Arbor, Michigan, USA.
  • Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: DLBhattMD@post.Harvard.edu.
  • School of Public Health, SUNY Downstate Health Sciences University, Brooklyn, New York, USA; University of Colorado School of Medicine, Aurora, CO, USA; CPC Clinical Research, Aurora, Colorado, USA.
  • Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Li Ka Shing Knowledge Institute, St. Michael's Hospital, and University of Toronto, Toronto, Ontario, Canada.
  • University of Texas Southwestern Medical Center, and Parkland Health and Hospital System, Dallas, Texas, USA.

Zitieren

APA

Pitt, B., Bhatt, D. L., Szarek, M., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., Lund, L. H., Komajda, M., Testani, J. M., Wilcox, C. S., Ponikowski, P., Lopes, R. D., Ezekowitz, J. A., Sun, F., Davies, M. J., …, & SOLOIST-WHF Investigators (2023). Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events. JACC: Heart Failure, 11(8), 879-889. https://doi.org/10.1016/j.jchf.2023.05.026

Vancouver

Pitt B, Bhatt DL, Szarek M, Cannon CP, Leiter LA, McGuire DK, et al. Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events. JACC: Heart Failure. 2023;11(8):879-889. doi:10.1016/j.jchf.2023.05.026

BibTeX
@article{Pitt2023,
  author = {Pitt, Bertram and Bhatt, Deepak L and Szarek, Michael and Cannon, Christopher P and Leiter, Lawrence A and McGuire, Darren K and Lewis, Julia B and Riddle, Matthew C and Voors, Adriaan A and Metra, Marco and Lund, Lars H and Komajda, Michel and Testani, Jeffrey M and Wilcox, Christopher S and Ponikowski, Piotr and Lopes, Renato D and Ezekowitz, Justin A and Sun, Franklin and Davies, Michael J and Verma, Subodh and Kosiborod, Mikhail N and Steg, Ph Gabriel and SOLOIST-WHF Investigators, SOLOIST-WHF Investigators},
  title = {Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events},
  journal = {JACC: Heart Failure},
  year = {2023},
  volume = {11},
  number = {8},
  pages = {879--889},
  doi = {10.1016/j.jchf.2023.05.026}
}
Kostenlos starten →